PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Immunol Lett. Author manuscript; available in PMC 2013 January 30.
Published in final edited form as:
PMCID: PMC3243824
NIHMSID: NIHMS337140

Potential Role for Alternatively Activated Macrophages in the Secondary Bacterial Infection During Recovery from Influenza

Abstract

Purpose

Secondary bacterial infections are a common complication of influenza. Innate immune host defenses appear to be impaired following influenza, leading to susceptibility to subsequent bacterial infections. Alternatively activated macrophages (AAM) in the lungs may play a critical role in eliciting the hypersusceptibility to secondary bacterial pneumonia.

Methods

C57BL6 mice were challenged with sublethal doses of the mouse-adapted A/PR/8/34 (PR8) influenza virus or saline and allowed to recover. At complete recovery (day 14), mice were re-challenged with sublethal doses of Streptococcus pneumoniae serotype 3 (Sp3).

Results

PR8-recovered mice developed a rapidly fatal pulmonary infection to a 100-fold sublethal pneumococcal challenge, whereas PR8-naive mice demonstrated no mortality or illness. The cytokines which induce AAM (IL-4 and IL-13) and the expression of genes associated with AAM (Arginase-1, FIZZ1, and YM1) were elevated after PR8 infection. Flow cytometry suggests that alveolar macrophages demonstrate the AAM-phenotype, as indicated by MGL-1 and MHCII expression, in response to PR8 infection. Recovery from PR8 was associated with blunted cytokine responses to TLR ligands.

Conclusions

The mechanisms of immune regulation during recovery from influenza are being elucidated. We provide evidence that pulmonary AAM are induced during influenza infection and may contribute to the elicitation of hypersusceptibility to a secondary bacterial infection.

Keywords: influenza, secondary pneumonia, alveolar macrophage, alternative activation

1. Introduction

A severe bacterial infection is commonly associated with influenza and is a significant contributor to the excess morbidity and mortality of influenza. In fact, the majority of deaths during the 1918 H1N1 [1], 1957 H2N2 [2,3], and 1968 H3N2 [4] pandemics are believed to be due to a secondary bacterial pneumonia. During interpandemic influenza, secondary bacterial infections may account for ~25% of influenza-associated hospitalizations [5,6]. Since more effective treatment strategies for influenza should address this frequent complication, studies directed at elucidating the mechanisms involved in inducting this hypersusceptibility to secondary infection are needed.

Although a secondary bacterial pneumonia often occurs during the primary viral infection, the risk continues to exist after resolution of influenza [2]. The late bacterial pneumonia has been hypothesized to be due, in part, to impaired host defenses [7,8]. Indeed, there is a sustained desensitization of alveolar macrophage Toll-like receptors (TLR) for at least 6 weeks after an influenza infection [9], indicating a window of susceptibility to secondary bacterial pathogens. Post-influenza resident pulmonary macrophages are impaired in their ability to engulf and kill bacteria [10,11]. Both the down-regulation and expression of the class A scavenger receptor MARCO on alveolar macrophages [12] and excessive IL-10 production [13] contribute to increased susceptibility to secondary bacterial pneumonia. Therefore, airway macrophage biology appears to be modulated after encountering an influenza infection.

The recognition of “alternatively activated macrophages” (AAM) has called attention to macrophage “plasticity” and the potential of environmental signals to alter macrophage differentiation. The pro-inflammatory “classical” macrophage (CM) is known for effective early host defenses and antimicrobial activity. CM differentiate in response to interferon-gamma (IFN-γ) and produce inducible nitric oxide synthase (iNOS) to generate nitric oxide (NO) and other reactive oxygen species, for bacterial killing. In contrast, AAM demonstrate poor bactericidal activity. AAM are associated with the maintenance of tissue homeostasis or are involved with tissue remodeling, wound healing and the dampening of inflammatory responses [14,15]. Furthermore, AAM differentiate in response to Th2 cytokines, IL-4 and IL-13, and produce arginase-1 (Arg-1) which competes with iNOS for arginine to produce L-ornithine and urea, rather than NO.

Due to the importance of an intact early innate immune response on the success of defending against a secondary infection, we explored the potential role of AAM. The hypothesis is that AAM may be critically involved in limiting the potential damage of the inciting pro-inflammatory primary influenza infection and promote tissue repair and healing, as a result of the injury from this initial event. In so doing, AAM may also contribute to a hypersusceptibility to a secondary bacterial infection because of the induction of poor antibacterial activity.

2. Materials and methods

2.1. Influenza

The A/PuertoRico/08/1934 (PR8) virus was grown in allantoic fluid of 10-day-old specific pathogen-free embryonated chicken eggs, aliquoted, and stored in −80°C. The determination of viral titers in the viral stocks, bronchoalveolar lavage (BAL) fluid, or tissue homogenates was performed with a 50% tissue culture infective dose (TCID50) assay. Titers are expressed as the reciprocal of the dilution that corresponds to 50% virus growth in Madine Darby canine kidney (MDCK) cells.

2.2 Bacteria

The Streptococcus pneumoniae serotype 3 (Sp3) isolate (ATCC 6303; Manassas, VA, USA) was grown in Brain Heart Infusion Broth at 37°C plus 5% CO2 overnight, aliquoted into equal volumes of glycerol, and stored in −80°C. The counts of the bacterial stocks, challenge inoculum, BAL fluid, or tissue homogenates was calculated from the colonies that grew on 5% sheep blood agar plates.

2.3 Animal Infections

All experiments involved 6–8 week old female, C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME, USA) that were handled in accordance with protocols approved by the Institutional Animal Care and Use Committee of the University of Maryland School of Medicine. Within one hour prior to challenge, frozen stocks of PR8 or Sp3 were diluted to the desired challenge concentration, in sterile, endotoxin-free phosphate buffered saline (PBS; Biosource International, Rockville, MD, USA). Mice were anesthetized with isoflurane (Baxter; Deerfield, IL, USA) prior to the deposition of 10–20 μl of challenge inoculum to a single nare. Each mouse was followed daily for weights and clinical scoring. Prospectively assigned mice were followed for survival or euthanized for harvesting of tissue, using sterile techniques.

2.4 Splenocytes

Individual spleens were obtained and homogenized as previously described [16]. Splenocytes, at a concentration of 1×106 cells/ml in 24-well plates, were stimulated overnight with the following agonists: E. coli O111:B4 LPS (List Biological Laboratories, Campbell, CA, USA), CpG ODN 10103 (Coley Pharmaceutical Group, Ontario,Canada), and Pam3Cys (EMC Microcollections, Tubingen, Germany). Supernatants were collected for cytokine analysis.

2.5 Flow Cytometry

Lungs were perfused with ice cold PBS and incubated in Collagenase D (Roche, Indianapolis, IN, USA) plus DNase I (USB, Santa Clara, CA, USA) solution for 30 minutes at 37°C. After passing the cells through a cell strainer, RBCs were lysed and the cells were washed. Lung cells (1–2 × 106) were re-suspended in FACS buffer (PBS, 3% FBS, 1% Sodium Azide, 1 mM EDTA), labeled and analyzed, as previously described [17]. Cells were stained for viability (Vivid, Live/Dead Fixable Dead Cell Stain kit; Invitrogen Corporation, Carlsbad, CA, USA) and the following flurochromes: CD19-eFluor450, CD11c-PE-Cy7, MHCII-Alexa700, NK1.1 PacBlue and F4/80-APC-Cy7 (eBioscience, San Diego, CA, USA);, Gr1-PerCP-Cy5.5, and CD11b-APC (BD Bioscience, San Jose, CA, USA); CD3-PacBlue (Caltag, Burlingame, CA, USA);; and MGL-1-PE (Santa Cruz Biotechnology, Santa Cruz, CA, USA) as well as their isotype controls. Cells were fixed with 1% formalin and stored at 4ºC until analyzed with a BD LSR II flow cytometer and FlowJo software (Tree Start Inc, Ashland, OR, USA).

2.6. Cytokine Expression and Production

Total cellular RNA in lungs was extracted and purified using TRIzol (Invitrogen). Real-time RT-PCR was performed, with an ABI 7900HT (Applied Biosystems, Carlsbad, CA, USA) sequence detection system and software, using primer sequences as previous described [18]. Relative mRNA level for specific genes are reported as relative gene expression normalized to untreated control samples. The cytokine production was quantified as previously described [16] using commercially available ELISA detection kits. Concentrations were calculated using the supplied standards and SoftPro (Molecular Dynamics, Sunnyvale, CA, USA).

2.8. Statistical analysis

Individual means were compared using a non-paired Student’s t test, Mann-Whitney Rank Sum test, or McNemar’s paired and ranked non-parametric test. Survival differences were determined using Kaplan-Meier survival plots and analyzed by a Log-rank test. Results were considered significant with two-sided p-values < 0.05. GraphPad Prism v5.0 (San Diego, CA, USA) was used to perform these statistical calculations.

3. Results

3.1. Hypersusceptibility to secondary pneumococcal pneumonia post-influenza infection

When C57BL/6 mice are challenged intranasally with 2×104 TCID50 of PR8, there is ~65% mortality by day 9. In contrast, mice that were challenged with a 10-fold sublethal dose of PR8 (2×103 TCID50) developed illness without mortality. Clinical illness and weight loss peaked at day 7 post-sublethal PR8 (2×103 TCID50), with an average loss of ~15% of original weight, and by day 10 mice were in recovery, as reflected by increased activity and weight gain [Figure 1A]. In sublethal infection, viable virus peaked between days 3 and 7 but was completely cleared by day 10, coinciding with clinical recovery [Figure 1B]. On day 14, the sublethally infected mice fully recovered their weights. There was no live virus present and histological examination of the lungs demonstrated the absence of inflammatory infiltrates and the return of ciliated epithelium [Figure 1C]. Therefore, mice infected with sublethal PR8 (2×103 TCID50) appear to have fully recovered from the primary influenza infection by day 14.

Figure 1
Recovery from primary PR8 influenza strain infection

It has been previously shown that mice are highly susceptible to a secondary bacterial infection when given a pneumococcal co-infection on day 7 of challenge with PR8, when the virus is still present [19,20,21]. However, when we administered a 100-fold sublethal dose of Sp3 (5×103 CFU) to PR8-recovered mice (day 14 from 2×103 TCID50 PR8), we observed that mice remained highly-susceptible, rapidly succumbing to an otherwise sublethal pneumococcal pneumonia with deaths occurring within 3–4 days of the secondary infection [Figure 2A]. On the other hand, saline control mice (i.e. PR8-naive) that received the 100-fold sublethal dose of Sp3 demonstrated no clinical illness, weight loss, or mortality. The mortality of the PR8-recovered mice (2×103 TCID50) was associated with a marked inflammatory pulmonary infiltrate, by histological examination, as early as 48 hours from the onset of secondary infection [Figure 2B]. But, saline control mice (PR8-naïve) that received the same sublethal Sp3 challenge demonstrated little, if any, lung pathology. The clinical illness and pulmonary infiltrates of the PR8-recovered (2×103 TCID50) mice were associated with overwhelming pneumococcal infection which rapidly and widely disseminated beyond the lungs, as demonstrated by bacterial colony counts from the lungs, blood, and spleens at 48 and 72 hours post-secondary infection [Figure 2C]. Meanwhile, the saline control mice (PR8-naïve) cleared the pneumococci from the lungs in <48 hours, and had no evidence of peripheral dissemination. Therefore, influenza-primed mice were hypersusceptible to a lethal overwhelming secondary bacterial infection, even during recovery from influenza and viral clearance.

Figure 2
Lethality of secondary Sp3 infection during recovery (14 days) from a primary influenza infection

3.2 The potential role of AAM

The pro-inflammatory response from an influenza infection must be balanced by regulatory and inhibitory effector mechanisms, thereby protecting bystander tissue damage from the effects of over-inflammation and promoting host tissue repair after viral clearance, preserving oxygenation [22,23]. Because AAM are associated with the regulation of inflammatory responses [15,24], we hypothesized that AAM would be present in the lungs of mice in recovery from influenza. Consistent with our hypothesis, there was an increase in gene expression (by RT-PCR) of the direct inducers of AAM, IL-4 and IL-13, on days 7 and 14 of influenza infection, when compared to uninfected controls [Figure 3A]. Naive mice challenged with sublethal Sp3 alone demonstrated little to no detectable pulmonary cytokine response (data not shown). Furthermore, the prototypic markers of AAM: Arg-1, Ym1, and “found in inflammatory zone 1” (FIZZ1) were also significantly elevated through influenza infection and recovery (day 14) [Figure 3B]. In addition, anti-inflammatory (IL-10 and TGF-β) cytokines, which are intimately associated with AAM, were elevated from day 3 (acute infection) through day 14 (recovery) of infection [Figure 3C] As expected, and in agreement with previous reports [25], pro-inflammatory cytokines (TNF-α, IL-6, and IFN-β) were also detected [Figure 3D]. Importantly, the TNF-α and IL-6 response peaked early (day 3) and before the IL-10 and TGF-β responses (day 7), which suggests that immune-regulation is a dynamic process during active viral replication. These data imply the induction of pulmonary AAM, which is preceded by the pro-inflammatory response of the influenza infection.

Figure 3
Gene expression associated with AAM

Flow cytometry was performed to further characterize the inflammatory infiltrate. The macrophage galactose-type C-type lectin (MGL-1; clone ER-MP23) has been described as a marker of AAM in the airways [26]. MGL-1 specifically identified AAM, when tested with in vitro generated AAM (primary peritoneal macrophages cultured with 40 ng/ml of IL-4, 48 hours); whereas CM (PBS treated primary peritoneal macrophages) did not stain for MGL-1 [Figure 4A]. We then used MGL-1 in combination with other markers of innate cells to assess the presence of AAM within the lungs of mice in our model of secondary bacterial infection. After eliminating lymphocyte lineage positive (removal of T and B lymphocytes as well as NK cells) and non-viable cells, innate immune cells were identified by the expression of Gr-1, CD11b, CD11c, MHCII, and F4/80. We found that alveolar macrophages (Gr-1 CD11b CD11chigh, autofluorescent cells) stained positive for MGL-1. However neutrophils (Gr-1+) (not shown), conventional dendritic cells (Gr-1 CD11b+ CD11c+, which were also MHCII+), and CM (Gr-1 F4/80+ CD11b+ CD11c) failed to stain for MGL-1 [Figure 4B].

Figure 4
Flow cytometric identification of the AAM phenotype

Next, we measured these cellular populations during the course of influenza infection with or without a secondary pneumococcal infection, using the same sublethal doses of PR8 and Sp3 as in our previous experiments. In the resting state (naïve mice), alveolar macrophages expressed MGL-1, but had low constitutive expression of MHCII. We defined the activated state of AAM as the alveolar macrophage population which expressed both MGL-1 and upregulated MHCII expression [15]. During influenza infection, these pulmonary AAM were elevated in the lungs of mice at day 7 post-influenza infection and remained elevated through day 14 [Figure 5A]. We found that both the percentage and total numbers of AAM in the lungs remained elevated at day 14 [Figure 5B & 5C]. Although CM was also elevated during influenza infection [Figure 5D], the timing of the increase in AAM population correlated with the onset of gene expression data for AAM markers [Figure 4]. These data support the induction of an activated state of the AAM-like phenotype among alveolar macrophages during influenza infection and these cells, unlike CM, remain through recovery.

Figure 5
Kinetics of lung AAM

3.3. Host innate immunity is impaired during recovery from influenza

Since there is previous evidence that alveolar macrophages respond poorly to TLR ligands during recovery from influenza infection [9] and we imply that these may be AAM, we explored whether the cytokine responses of a distal, extra-pulmonary organ may also be affected (i.e. systemic versus local involvement). Splenocytes were harvested at 0 (control), 3 (active infection), and 14 days (recovery) after sublethal influenza infection and stimulated overnight with the following agonists: LPS 100 ng/ml, CpG 10 μg/ml, Pam3Cys 100 ng/ml, or media alone. These stimuli were selected to represent the TLRs most likely to be encountered during a bacterial infection. We found there was significant blunting of TNF-α, IL-6, IL-12, and IL-10 production following stimulation with any of the 3 ligands at both days 3 and 14 of influenza infection, compared to control splenocyte responses [Figure 6], which suggests systemic effects from an infection localized to the lungs. Similar trends for decreased responses were also found for MIP-1α and KC. (not shown) Therefore, we show that host innate immune hyporesponsiveness occurs as early as 3 days after infection and persists until at least 2 weeks post-infection. Since these responses were observed in splenocytes, we may conclude that the perturbation of the innate immune response is not compartmentalized only to the lungs.

Figure 6
Blunted splenocyte responses to TLR stimuli

4. Discussion

A serious secondary bacterial infection commonly complicates the recovery from a preceding influenza infection. Our mouse model faithfully reproduces the human clinical scenario, in that we show recovery from influenza infection is associated with susceptibility to a subsequent and normally sublethal dose of bacteria. The fact that the pulmonary system, open to the external environment, normally remains immunologically quiescent, despite encountering a constant cascade of inhaled foreign antigen, is a testament to the highly regulated nature of the lung milieu. When the host is infected with influenza, an effective pulmonary response should result in sterilizing immunity while avoiding excessive bystander tissue damage and preventing “cytokine storm” to maintain oxygenation. The balance and regulation of inflammation during infection and the promotion of resolution during recovery from influenza remain underappreciated. However, AAM are increasingly recognized as important contributors to wound healing and dampening of pro-inflammatory responses as well as eliciting pathologic Th2 (allergy) responses [14,15].

This model of infection did not explore the potential for viral-induced (such as the role of PB1-F2 [27] or the neuraminidase [28,29]) or bacteria-specific mechanisms [30,31] which have been shown to play a role in the pathogenesis of the secondary bacterial pneumonia, during acute infection (concomitant with the pro-inflammatory response). Rather, the focus of our model was to allow recovery from the initial influenza infection, such that there may be no biasing of our observations with a dual (virus and bacteria) infection. The majority of secondary bacterial infection models interrogate influenza post-infection day 7 (references), when the virus is still present, and only a few have investigated the host after recovery (reference). Furthermore, by allowing recovery from influenza, we minimized the potential effect of denuded respiratory epithelium and exposed basement membrane as contributory factors that may allow the bacteria to evade host defenses.

Although these studies were intended to define the model, we show that pulmonary AAM are induced during influenza infection and remain present during recovery. The cytokines necessary to induce alternative activation, IL-4 and IL-13 [15,32], were detected and the markers unique for AAM (Arg-1, FIZZ1, and Ym1) [33] were also expressed. Finally, alveolar macrophages, with an AAM-like phenotype were identified. Surprisingly, we also found evidence for systemic hyporesponsiveness to non-replicating TLR agonists, as evidenced by the altered responses of ex vivo splenocytes. These data support the presence and a potential role for the AAM in post-influenza secondary bacterial infection.

In the present study we do not definitively show AAM directly contributed to the hypersusceptibility phenotype. Further mechanistic studies are ongoing. However, another potential explanation for the presence of AAM is that they represent a bystander population; a result of the inflammation by influenza but having little role in eliciting the hypersusceptibility phenotype. On the other hand, there is substantial circumstantial evidence that AAM do contribute to hypersusceptibility. A reduction in bacterial opsonophagocytosis following influenza has been well-established [11,34]; impaired opsonophagocytosis is also observed with AAM [35]. And, we do find that AAM are unable to generate NO in response to LPS (unpublished data). Alveolar macrophage engulfment of apoptotic inflammatory cells (efferocytosis), such as during influenza infection, triggers a reduction in clearance of S. pneumoniae and the release of TGF-β and IL-10 [34]. Furthermore, alveolar macrophage responses to bacterial stimuli are blunted [9] and the negative homeostatic pressure, through the upregulation of the repressive activity of CD200R ligation, increases in response to influenza infection and through resolution (day 14) [36].

Our results add to the increasing evidence that host defenses, especially those of alveolar macrophages, are impaired following influenza infection. We show that AAM may play a role in eliciting the susceptibility to a secondary bacterial infection subsequent to an influenza infection, even after clearance and recovery from the acute viral infection. Future mechanistic studies should be performed to determine whether AAM are necessary and sufficient for eliciting the hypersusceptibility to a secondary bacterial infection.

Highlights

  • Mice that have fully recovered from a primary influenza infection are highly susceptible to a secondary bacterial infection.
  • Cytokine responses to TLR stimulation are blunted, after influenza infection.
  • The initial pro-inflammatory cytokine (IL-6 and TNF-α) response of an influenza infection is followed by anti-inflammatory cytokines (IL-10 and TGF-β).
  • Gene expression of markers of AAM (Arg-1, FIZZ1, YM1) and the cytokines necessary to induce AAM (IL-4 and IL-13) are elevated after influenza infection.
  • Alveolar macrophages which demonstrate an AAM phenotype are induced after influenza infection.

Acknowledgments

This study was supported by National Institutes of Health Research Grant NCRR K12-RR-023250 (WHC), RO1-HL-086933 (ASC) and The Passano Foundation (WHC). None of the other authors have conflicts to disclose.

Abbreviations

AAM
alternatively activated macrophage
CM
classical macrophage
PR8
mouse-adapted A/PR/8/34 influenza virus
Sp3
Streptococcus pneumoniae serotype 3

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198:962–970. [PMC free article] [PubMed]
2. LOURIA DB, BLUMENFELD HL, ELLIS JT, KILBOURNE ED, ROGERS DE. Studies on influenza in the pandemic of 1957–1958. II. Pulmonary complications of influenza. J Clin Invest. 1959;38:213–265. [PMC free article] [PubMed]
3. HERS JF, MASUREL N, MULDER J. Bacteriology and histopathology of the respiratory tract and lungs in fatal Asian influenza. Lancet. 1958;2:1141–1143. [PubMed]
4. Lindsay MI, Jr, Herrmann EC, Jr, Morrow GW, Jr, Brown AL., Jr Hong Kong influenza: clinical, microbiologic, and pathologic features in 127 cases. JAMA. 1970;214:1825–1832. [PubMed]
5. Kashiwagi S, Ikematsu H, Hayashi J, Nomura H, Kajiyama W, Kaji M. An outbreak of influenza A (H3N2) in a hospital for the elderly with emphasis on pulmonary complications. Jpn J Med. 1988;27:177–182. [PubMed]
6. Oliveira EC, Marik PE, Colice G. Influenza pneumonia: a descriptive study. Chest. 2001;119:1717–1723. [PubMed]
7. Ballinger MN, Standiford TJ. Postinfluenza bacterial pneumonia: host defenses gone awry. J Interferon Cytokine Res. 2010;30:643–652. [PubMed]
8. van der Sluijs KF, van der PT, Lutter R, Juffermans NP, Schultz MJ. Bench-to-bedside review: bacterial pneumonia with influenza - pathogenesis and clinical implications. Crit Care. 2010;14:219. [PMC free article] [PubMed]
9. Didierlaurent A, Goulding J, Patel S, Snelgrove R, Low L, Bebien M, Lawrence T, van Rijt LS, Lambrecht BN, Sirard JC, Hussell T. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med. 2008;205:323–329. [PMC free article] [PubMed]
10. Nickerson CL, Jakab GJ. Pulmonary antibacterial defenses during mild and severe influenza virus infection. Infect Immun. 1990;58:2809–2814. [PMC free article] [PubMed]
11. Weeks JN, Boyd KL, Rajam G, Ades EW, McCullers JA. Immunotherapy with a combination of intravenous immune globulin and p4 Peptide rescues mice from postinfluenza pneumococcal pneumonia. Antimicrob Agents Chemother. 2011;55:2276–2281. [PMC free article] [PubMed]
12. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med. 2008;14:558–564. [PubMed]
13. van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Pater JM, Florquin S, Goldman M, Jansen HM, Lutter R, van der PT. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol. 2004;172:7603–7609. [PubMed]
14. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–969. [PMC free article] [PubMed]
15. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23–35. [PubMed]
16. Chen WH, Basu S, Bhattacharjee AK, Cross AS. Enhanced antibody responses to a detoxified lipopolysaccharide-group B meningococcal outer membrane protein vaccine are due to synergistic engagement of Toll-like receptors. Innate Immun. 2010;16:322–332. [PubMed]
17. Toapanta FR, Ross TM. Impaired immune responses in the lungs of aged mice following influenza infection. Respir Res. 2009;10:112. [PMC free article] [PubMed]
18. Shirey KA, Cole LE, Keegan AD, Vogel SN. Francisella tularensis live vaccine strain induces macrophage alternative activation as a survival mechanism. J Immunol. 2008;181:4159–4167. [PMC free article] [PubMed]
19. Karlstrom A, Boyd KL, English BK, McCullers JA. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis. 2009;199:311–319. [PMC free article] [PubMed]
20. LeVine AM, Koeningsknecht V, Stark JM. Decreased pulmonary clearance of S. pneumoniae following influenza A infection in mice. J Virol Methods. 2001;94:173–186. [PubMed]
21. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis. 2002;186:341–350. [PubMed]
22. Lambrecht BN. Alveolar macrophage in the driver’s seat. Immunity. 2006;24:366–368. [PubMed]
23. Snelgrove RJ, Godlee A, Hussell T. Airway immune homeostasis and implications for influenza-induced inflammation. Trends Immunol. 2011 [PubMed]
24. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32:593–604. [PubMed]
25. Smith MW, Schmidt JE, Rehg JE, Orihuela CJ, McCullers JA. Induction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza. Comp Med. 2007;57:82–89. [PMC free article] [PubMed]
26. Raes G, Brys L, Dahal BK, Brandt J, Grooten J, Brombacher F, Vanham G, Noel W, Bogaert P, Boonefaes T, Kindt A, Van den BR, Leenen PJ, De BP, Ghassabeh GH. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol. 2005;77:321–327. [PubMed]
27. McAuley JL, Hornung F, Boyd KL, Smith AM, McKeon R, Bennink J, Yewdell JW, McCullers JA. Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe. 2007;2:240–249. [PMC free article] [PubMed]
28. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis. 2003;187:1000–1009. [PubMed]
29. Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis. 2005;192:249–257. [PMC free article] [PubMed]
30. King QO, Lei B, Harmsen AG. Pneumococcal surface protein A contributes to secondary Streptococcus pneumoniae infection after influenza virus infection. J Infect Dis. 2009;200:537–545. [PMC free article] [PubMed]
31. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006;19:571–582. [PMC free article] [PubMed]
32. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992;176:287–292. [PMC free article] [PubMed]
33. Loke P, Nair MG, Parkinson J, Guiliano D, Blaxter M, Allen JE. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype. BMC Immunol. 2002;3:7. [PMC free article] [PubMed]
34. Medeiros AI, Serezani CH, Lee SP, Peters-Golden M. Efferocytosis impairs pulmonary macrophage and lung antibacterial function via PGE2/EP2 signaling. J Exp Med. 2009;206:61–68. [PMC free article] [PubMed]
35. Varin A, Mukhopadhyay S, Herbein G, Gordon S. Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretion. Blood. 2010;115:353–362. [PubMed]
36. Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L, Gwyer E, Sedgwick JD, Barclay AN, Hussell T. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol. 2008;9:1074–1083. [PubMed]